BioStock: Respiratorius turns its focus to COPD and severe asthma
Much has gone the way of Respiratorius’ main candidate, the cancer drug VAL001. Following the EMA’s recommendation to go directly to phase III, they are now looking for a partner to reach an agreement and take the candidate further. Thus, more operational focus is now being placed on the next candidate in the development queue, RESP9000 for the treatment of COPD and severe asthma.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se